Harry G. Brittain
27Patents
4h-index
10Co-inventors
60Inventor score
Filing activity: Sep 8, 1986 → Feb 24, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4861727A | Luminescent oxygen sensor based on a lanthanide complex | Emerging Cross-Sectional Technologies | 65 | Expired |
| US5190729A | Luminescent oxygen sensor based on a lanthanide complex | Physics | 27 | Expired |
| US8173625B2 | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine | Chemistry; Metallurgy | 16 | Active |
| US8304404B2 | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine | Chemistry; Metallurgy | 4 | Active |
| US7279579B2 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 2 | Expired |
| US8975272B2 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 2 | Active |
| US10166228B2 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 1 | Active |
| US9289438B2 | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine | Chemistry; Metallurgy | 1 | Active |
| US9603937B2 | Platform drug delivery system utilizing crystal engineering and theanine dissolution | Emerging Cross-Sectional Technologies | 1 | Active |
| US8685948B2 | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine | Chemistry; Metallurgy | 1 | Active |
| US9289439B2 | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine | Chemistry; Metallurgy | 1 | Active |
| US9289440B2 | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine | Chemistry; Metallurgy | 1 | Active |
| US8476250B2 | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine | Chemistry; Metallurgy | 1 | Active |
| US9603939B2 | Platform drug delivery system utilizing crystal engineering and theanine dissolution | Emerging Cross-Sectional Technologies | 1 | Active |
| US9556189B2 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 1 | Active |
| US8389540B2 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 1 | Active |
| US9603938B2 | Platform drug delivery system utilizing crystal engineering and theanine dissolution | Emerging Cross-Sectional Technologies | 1 | Active |
| US8735420B2 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 1 | Active |
| US9365580B2 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 0 | Active |
| US9980958B2 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 0 | Active |
| US10548905B2 | Amorphous onapristone compositions and methods of making the same | Chemistry; Metallurgy | 0 | Active |
| US9827240B2 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 0 | Active |
| US10328070B1 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 0 | Active |
| US9221830B2 | Polymorphic forms of naltrexone | Chemistry; Metallurgy | 0 | Active |
| US10376464B2 | Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.